Pune, India, December, 2017/MRFR Press Release/- Market Research Future published a half Cooked research report on “Global Antibody drug conjugate Market Research Report - Forecast till 2027” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2027.
Antibody drug conjugates are the targeted therapy for the treatment of people suffering with cancer. It is the important class of highly potent biopharmaceutical drugs, with intend to target and kill only cancer cells. Antibody drug conjugates have quality of sensitive discrimination between healthy and diseased tissue. It represent an innovative therapeutic application that combines the unique, high specificity, properties and anti-tumor activity of monoclonal antibodies (mAbs) that are tumor-specific but not sufficiently cytotoxic. According to National Instituted of Health (NIH) it has been found that in 2016, a projected 1,685,210 new cases of cancer will be detected in the United States and 595,690 individuals will die from the disease which further increases the growth of the market.
Global Antibody drug conjugate Market – Overview
The global antibody drug conjugate market is rising with a swift phase; mainly owing to increase in patient population suffering with cancer. This therapy have ability to treat different type of cancer such as endometrial and breast cancer. According to WHO, in 2015, around 570,000 women died owing to breast cancer globally, which are approximately 15% of all cancer deaths among women. Breast cancer is most frequent cancer among the women, and impacting around 1.5 million women every years. Rising consumer awareness about treatment with antibody drug conjugate therapy and increasing population globally leads the antibody drug conjugate market.
Companies are continuously invent new products to capture the market globally. Thus major players invest more in merger, collaboration, and acquisition, in order to lead the global market. In this regards, Jazz Pharmaceuticals and ImmunoGen, Inc. Announce a Strategic Collaboration and Option Agreement to Develop and Commercialize Antibody-Drug Conjugate Products. Where ImmunoGen will be responsible for the developing of the three ADC programs prior to any potential opt-in by Jazz. These collaboration help to introduce new quality drugs for the treatment of the cancer.
In 2017, Vaccinex Inc and Catalent Biologics to collaborate on antibody-drug conjugate development. In this collaboration company will combine the ActivMAb antibody with Catalent’s SMARTag conjugation technology, for generating unique and differentiated molecule to treat cancers. These collaboration also help in expanding the network around the globe. Which help companies to reach the patient population and capturing the market. Additionally, research and development will help company to leads the market. Increasing in cancer population globally is the factors that leads the market of antibody drug conjugate.
Seattle Genetics (U.S.), ImmunoGen, Inc.(U.S.), Roche Holding AG (Switzerland), Genentech (U.S.), Concortis Biotherapeutics (U.S.), Agensys, Inc. (U.S.), Antikor (U.K), Vaccinex Inc (U.S.) are some of the leading players at the cutting edge of the competition in the market of antibody drug conjugate, globally.
Global Antibody drug conjugate Market - Regional Analysis
The market of antibody drug conjugate is much higher in the Americas region, owing to high presence of population diagnosed with cancer and also have awareness of healthcare. Thus, market players have good opportunity to maximize their profit with in this region owing to high awareness of healthcare awareness. According to American Society of Clinical Oncology (ASCO) the 5-year survival rate for stage I NSCLC is about 47% which falls drastically to 10% for stage III. The 5-year survival rate for stage IV NSCLC is just around 1%.
Europe is also consider huge market for antibody drug conjugate players, owing to present of huge population affected with cancer. Government are more focusing on research and development to introduce new drugs for providing the best treatment to their citizen. According to Cancer research UK, in 2014, new cases of cancer are 356,860, including 579 cases of bone cancer.
Asia Pacific region is considering the huge market. Whereas country like India and china of are considering fastest growing region due to presence of huge population suffering with cancer, additionally they are open to adopt new technology, and best treatment option from developed countries in order to improve the quality of life for their public. According to the World Cancer Research Fund International, in 2015, cancer was responsible for 8.8 million deaths, and is the second leading cause of death across the globe.
There is the rise in investment for the treatment of cancer in last few years, According to the IMS Institute for Health care Informatics, the global spending on oncology medicines was USD 100 billion in 2014, which rose to USD 107 billion in 2015.It also stated that the spending is expected to rise to nearly 150 billion by 2020.
Browse Full Report @ https://www.marketresearchfuture.com/reports/antibody-drug-conjugate-market-1113